NPM1 and acute myeloid leukemia: Another recent phase I clinical study explored Bleximenib in association with standard chemotherapy in a group of 22 newly diagnosed AML patients (11 KMT2A-rearranged and 11 NPM1-mutated), showing an acceptable safety profile with no DS or dose-limiting toxicities [113].